Treatment Strategy for Acquired Pure Red Cell Aplasia: a Systematic Review and Meta-analysis

Overview

Journal Blood Adv

Specialty Hematology

Date 2023 Aug 25

PMID 37624775

Authors

Herve Lobbes

Jean-Christophe Lega

Guillaume Le Guenno

Marc Ruivard

Sabine Mainbourg

Affiliations

Soon will be listed here.

Abstract

The treatment of autoimmune acquired pure red cell aplasia (aPRCA) is challenging. Guidelines are based on expert recommendations in the absence of controlled trials. We assessed the efficacy of the main treatment strategy through a systematic review and meta-analysis using MEDLINE, EMBASE, and the Cochrane Library up to September 2022. The overall response rate (ORR) was pooled using random-effects models. In total, 24 observational studies (19 retrospective, median follow-up of 48 months) encompassing 753 patients (49% male) were included. Primary aPRCA represented 57% of the cases. The risk of bias was moderate to high using the ROBINS-I tool. Substantial heterogeneity (I2 > 50%) was retrieved. Corticosteroids as monotherapy as first-line treatment (186 patients, 13 studies) provided an ORR of 47% (95% confidence interval [CI], 34-60). Cyclosporine A was the most frequently used immunosuppressant agent (384 patients, 18 studies), providing an ORR of 74% (95% CI, 66-82) with a similar ORR in first- (73%) and second-line (76%) treatment and when cyclosporin was used as monotherapy (83%) or with corticosteroids (77%). A total of 112 patients (10 studies) received cyclophosphamide, with an ORR of 49% (95% CI, 35-64), which was higher when cyclophosphamide was combined with corticosteroids (48%) and used in second-line treatment (58%) than in monotherapy (31%), and in first-line treatment (44%). Sirolimus use was reported only after cyclosporine A failure and provided an ORR of 87% (95% CI, 68-100; 64 patients, 3 studies). Substantial uncertainty remains regarding the best treatment strategy in the absence of high-quality evidence. This study was registered on the PROPERO database as #CRD42022360452.

Citing Articles

Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.

Gong Y, Li Y, Chen X, Yang H, Zhang Y, He G Ann Hematol. 2024; 103(8):3239-3242.

PMID: 38935319 DOI: 10.1007/s00277-024-05856-z.

Understanding Rare Anemias: Emerging Frontiers for Diagnosis and Treatment.

Vives Corrons J J Clin Med. 2024; 13(11).

PMID: 38892889 PMC: 11172750. DOI: 10.3390/jcm13113180.

A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia.

Yang L, Niu H, Zhang T, Cao Q, Liu M, Liu Y Ann Hematol. 2024; 103(6):1877-1885.

PMID: 38308019 DOI: 10.1007/s00277-024-05636-9.

References

Charles R, Sabo K, Kidd P, Abkowitz J . The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996; 87(11):4831-8. View

Masaoka A, Hashimoto T, Shibata K, Yamakawa Y, Nakamae K, Iizuka M . Thymomas associated with pure red cell aplasia. Histologic and follow-up studies. Cancer. 1989; 64(9):1872-8. DOI: 10.1002/1097-0142(19891101)64:9<1872::aid-cncr2820640920>3.0.co;2-0. View

Passweg J, Rabusin M . Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias. Autoimmunity. 2008; 41(8):660-5. DOI: 10.1080/08916930802198436. View

Kawano N, Nagahiro Y, Yoshida S, Yamashita K, Himeji D, Yokota-Ikeda N . Clinical characteristics and outcomes of 11 patients with pure red cell aplasia at a single institution over a 13-year period. Intern Med. 2013; 52(18):2025-30. DOI: 10.2169/internalmedicine.52.8291. View

Means Jr R . Pure red cell aplasia. Blood. 2016; 128(21):2504-2509. DOI: 10.1182/blood-2016-05-717140. View

Nakazawa H, Sakai K, Ohta A, Fujishima N, Matsuda A, Hosokawa K . Incidence of acquired pure red cell aplasia: a nationwide epidemiologic analysis with 2 registry databases in Japan. Blood Adv. 2022; 6(24):6282-6290. PMC: 9806328. DOI: 10.1182/bloodadvances.2021006486. View

Saffari A, Brosse I, Wiemer-Kruel A, Wilken B, Kreuzaler P, Hahn A . Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study. Orphanet J Rare Dis. 2019; 14(1):96. PMC: 6500021. DOI: 10.1186/s13023-019-1077-6. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View

Sorin B, Fadlallah J, Garzaro M, Vigneron J, Bertinchamp R, Boutboul D . Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia. Ann Hematol. 2023; 102(8):2059-2068. DOI: 10.1007/s00277-023-05340-0. View

10.

Wu Q, Wang X, Nepovimova E, Wang Y, Yang H, Kuca K . Mechanism of cyclosporine A nephrotoxicity: Oxidative stress, autophagy, and signalings. Food Chem Toxicol. 2018; 118:889-907. DOI: 10.1016/j.fct.2018.06.054. View

11.

Chalayer E, Costedoat-Chalumeau N, Beyne-Rauzy O, Ninet J, Durupt S, Tebib J . Bone marrow involvement in systemic lupus erythematosus. QJM. 2017; 110(11):701-711. DOI: 10.1093/qjmed/hcx102. View

12.

Fu R, Zhang T, Liu B, Song J, Wang G, Li L . The clinical characteristics and therapy response of patients with acquired pure red cell aplasia. Hematology. 2018; 23(9):639-645. DOI: 10.1080/10245332.2018.1470068. View

13.

Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K . Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008; 93(1):27-33. DOI: 10.3324/haematol.11655. View

14.

Malhotra P, Muralikrishna G, Varma N, Kumari S, Das R, Ahluwalia J . Spectrum of pure red cell aplasia in adult population of north-west India. Hematology. 2008; 13(2):88-91. DOI: 10.1179/102453308X315979. View

15.

Cholongitas E, Burra P, Vourli G, Papatheodoridis G . Safety and efficacy of everolimus initiation from the first month after liver transplantation: A systematic review and meta-analysis. Clin Transplant. 2023; 37(5):e14957. DOI: 10.1111/ctr.14957. View

16.

Kwong Y, Wong K, Liang R, Chu Y, Chan L, Chan T . Pure red cell aplasia: clinical features and treatment results in 16 cases. Ann Hematol. 1996; 72(3):137-40. DOI: 10.1007/s002770050151. View

17.

Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O . Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2012; 56(7):968-77. DOI: 10.1093/cid/cis1046. View

18.

Huang Y, Chen M, Yang C, Ruan J, Wang S, Han B . Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial. Leukemia. 2022; 36(5):1351-1360. DOI: 10.1038/s41375-022-01532-1. View

19.

Peng G, Yang W, Zhang L, Zhou K, Li Y, Li Y . Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia. Hematology. 2016; 21(3):138-43. DOI: 10.1080/10245332.2015.1101977. View

20.

Rivoisy C, Besse B, Girard N, Lioger B, Viallard J, Lega J . Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France. J Thorac Oncol. 2016; 11(3):391-9. DOI: 10.1016/j.jtho.2015.11.012. View